ifenprodil
Small moleculeexperimental
Ifenprodil, sold under the brand names Cerocral, Dilvax, and Vadilex, is a cerebral vasodilator that has been marketed in some countries, including in Japan, Hong Kong, and France. It is currently under development for treatment of a variety of additional indications. — Wikipedia
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2013 (NCT01896388)
Timeline
Indications
Mechanism of action
Glutamate NMDA receptor; GRIN1/GRIN2A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1- Mol. weight
- 325.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL305187 ↗
- WikipediaIfenprodil ↗
- ChEMBLCHEMBL37387 ↗
- ChEMBLCHEMBL1886888 ↗
- ChEMBLCHEMBL1256662 ↗
Also known as
- 2-(4-benzylpiperidino)-1-(4-hydroxyphenyl)-2-methyl-1-ethanol
- 4-benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol
- 61 91 rc
- alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine ethanol
- ifenprodil
- ifenprodil
- ifenprodil
- ifenprodil
- ifenprodil
- ifenprodil
- ifenprodil
- ifenprodil
- ifenprodil hydrochloride
- ifenprodil hydrochloride, (+-)-isomer
- ifenprodil, (r*,s*)-(+-)-isomer
- ifenprodil tartrate
- ifenprodil tartrate
- ifenprodil tartrate
- ifenprodil tartrate
- ifenprodil tartrate
- ifenprodil tartrate (1:1), (r-(r*,r*))-isomer
- ifenprodil tartrate (1:1), (r*,s*)-(+-)-(r-(r*,r*))-isomer
- ifenprodil tartrate (2:1), (r-(r*,r*))-isomer
- ifenprodil, tartrate(r-(r*,r*))-isomer
- rc 61-91
- rc 61-91
- vadilex
- vadilex
- vadilex
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06330077 | Phase 2 | Mar 31, 2024 | Assistance Publique - Hôpitaux de Paris |
| NCT04382924 | Phase 2/Phase 3 (Phase 3) | Jul 31, 2020 | Algernon Pharmaceuticals, Novotech |
| NCT04318704 | Phase 2 | Jun 30, 2020 | Algernon Pharmaceuticals |
| NCT01896388 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2013 | Chiba University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Algernon Pharmaceuticals | For profit | 2 | 2 | 2 | 2020 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Chiba University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Novotech | For profit | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1